Dongxu Zhai

Dongxu Zhai

Auto-generated profile, based on publicly available information

Dongxu Zhai

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College St., Toronto M5T 1R8, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in Science Advances
Verified
Journal Article
Open access
DZDongxu Zhai
Dongxu Zhai
SYShuxin Yan
Shuxin Yan
JSJames Samsom
James Samsom
LWLe Wang
Le Wang
PSPing Su
Ping Su
FLFang Liu
Fang Liu
While most research and treatments for multiple sclerosis (MS) focus on autoimmune reactions causing demyelination, it is possible that neurodegeneration precedes the autoimmune response. Hence, glutamate receptor antagonists preventing excitotoxicity showed promise in MS animal models, though blocking glutamate signaling prevents critical neuronal functions. This study reports the discovery of a small molecule that prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site. A machine learning approach was used to screen for small molecules targeting the AMPA receptor GluA2 subunit. The lead candidate has potent effects in restoring neurological function and myelination while reducing the immune response in experimental autoimmune encephalitis and cuprizone MS mouse models without affecting basal neurotransmission or learning and memory. These findings facilitate development of a treatment for MS with a different mechanism of action than current immune modulatory drugs and avoids important off-target effects of glutamate receptor antagonists. This class of MS therapeutics could be useful as an alternative or complementary treatment to existing therapies.